Review
Nature Reviews Microbiology 6, 349-362 (May 2008) | doi:10.1038/nrmicro1840
Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria
Jerry M. Wells1 & Annick Mercenier2 About the authors
Abstract
Studies of lactic acid bacteria (LAB) as delivery vehicles have focused mainly on the development of mucosal vaccines, with much effort being devoted to the generation of genetic tools for antigen expression in different bacterial locations. Subsequently, interleukins have been co-expressed with antigens in LAB to enhance the immune response that is raised against the antigen. LAB have also been used as a delivery system for a range of molecules that have different applications, including anti-infectives, therapies for allergic diseases and therapies for gastrointestinal diseases. Now that the first human trial with a Lactococcus strain that expresses recombinant interleukin-10 has been completed, we discuss what we have learnt, what we do not yet understand and what the future holds for therapy and prophylaxis with LAB.
- View At a Glance
Author affiliations
-
Host–Microbe Interactomics, University of Wageningen, Animal Sciences Department, P.O. BOX 338, 6700 AH, Wageningen, The Netherlands.
Email: jerry.wells@wur.nl -
Nestlé Research Center, Vers-chez-les-Blanc CH-1000, Lausanne 26, Nestlé Research Center, Lausanne, Switzerland.
Email: annick.mercenier@rdls.nestle.com
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Oral vaccination of mice against tetanus with recombinant Lactococcus lactisNature Biotechnology Research Article (01 Jul 1997)
In vivo transfer of plasmid from food-grade transiting lactococci to murine epithelial cellsGene Therapy Original Article
See all 14 matches for Research